Navigation Links
Minnesota partnership advances potential MS therapy
Date:4/17/2008

ROCHESTER/MINNEAPOLIS, Minn. A production laboratory founded by the Minnesota Partnership has transferred its first potential therapy a medication for multiple sclerosis to a processing plant in Minnesota. This step will complete purification of material to fully enable translation from preclinical to clinical development.

The antibody known as rHIgM22, developed at Mayo Clinic, was produced and purified in the Biotherapeutic Protein Production Laboratory created by a Partnership infrastructure award in 2006. This laboratory was developed within the Molecular and Cellular Therapeutics Facility on the St. Paul campus of the University of Minnesota. The therapy is under license to Acorda Therapeutics, Inc. (NASDAQ: ACOR), which is supporting the development of this potential therapy. This includes the Minnesota Partnerships transfer of remaining production and purification to Biovest, Inc., in Minneapolis.

The preclinical success and the promise of this program to date have only enhanced our commitment to the continued advancement of this potential new therapy for people with multiple sclerosis, says Ron Cohen, M.D., Acorda president and CEO. The Partnership has provided a mechanism for academic and commercial institutions to work together effectively in the early stages of developing a promising and innovative therapeutic approach to a very challenging condition.

The importance of the antibody as a promoter of myelin repair (remyelination) was recognized in studies using experimental animal models of multiple sclerosis. The studies were directed by Moses Rodriguez, M.D., a Mayo Clinic neurologist. Multiple sclerosis is a progressive disease, caused by damage to the myelin sheath that surrounds nerves. It can affect the brain and the spinal cord, leaving patients permanently disabled. The rHIgM22 antibody initiates the re-growth or repair of the damaged myelin sheath but has yet to be tested in patients.

The initial synthe
'/>"/>

Contact: Nick Hanson
hans2853@umn.edu
612-624-2449
University of Minnesota
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Securians Minnesota Life Continues to Climb Group Life Rankings
2. Fresh Air Campaign to Showcase Minnesotans Love of Smoke-Free Air
3. Four Minnesota Hospitals Rate High For Patient Safety and Quality
4. First-in-the-Nation Health Care Billing Policy Announced in Minnesota
5. Help is Available for Smokers Who Want to Quit as Minnesotas Smoke-Free Law Takes Effect Oct. 1
6. Maryland, Minnesota Go Smoke-free Oct. 1 - Pennsylvania Overdue in Following Suit
7. New National Medicaid Study: Minnesota Under Funds Seniors Nursing Home Care $167 Million Annually
8. Blue Cross and Partners to Host Combat Stress Conference for Minnesotas Health Care Professionals
9. TV Documentary Examines Three Decades of Tobacco Politics, Policies and People in Minnesota
10. Minneapolis Hosts National Conference on Tobacco or Health October 24-26 on Heels of Minnesotas Statewide, Smoke-Free Law
11. Mayo Clinic Calls for Thorough Review of Canadian Pacifics Acquisition of the Dakota, Minnesota & Eastern Railroad
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... iFitDress.com, a famous company of wedding dresses and special ... of 2014 glitter evening dresses . Moreover, the ... gowns. , iFitDress.com is one of the most loved ... in the recent years, not just because of its ... amicable services offered on its website. , The ...
(Date:7/21/2014)... MA (PRWEB) July 21, 2014 What ... extramarital affair have in common? You can find them ... Heart! The novel's main character, Miranda, lives on Martha’s ... meets Clay, a wealthy New Yorker, and becomes entangled ... of the Heart challenges readers to think about what ...
(Date:7/21/2014)... July 21, 2014 Executives from ... specializing in private healthcare practices, will participate in ... They will be showcasing their state-of-the-art capabilities and ... practices all over the United States as the ... continues to increase. Advice Media’s presence at IACA ...
(Date:7/21/2014)... 2014The Associated Press-NORC Center for Public Affairs Research has ... public,s opinions about what it means to be a ... survey, funded by the Robert Wood Johnson Foundation, sheds ... of their health care and doctors, as well as ... care decisions. The survey produces new and actionable data ...
(Date:7/21/2014)... 2014 (HealthDay News) -- Good parenting and life ... from low-income families, a new study suggests. ... and can lead to a number of illnesses, ... problems in both childhood and adulthood involve excessive ... heart disease, allergies and some cancers," study author ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: 2014 Glitter Evening Dresses For Worldwide Clients 2Health News:Thea Marsh Releases Debut Novel that Celebrates and Reaches out to Women Everywhere 2Health News:Advice Media to Attend the International Association of Comprehensive Aesthetics Conference (IACA) Targeting the Dental Profession 2Health News:National survey from AP-NORC examines perceptions of health care provider quality 2Health News:Life Skills, Parenting Classes May Cut Inflammation in Poor Kids 2
... past have argued about the implications of Hormone Replacement Therapy ... A new study, however, has gone further to show that ... developing breast cancer// if they consumed alcoholic beverages. ,The ... pattern and on whether they were on HRT currently or ...
... have found that people who take anti-depressants to relieve ... developing gastrointestinal bleeding. The study which was conducted over ... were compared for hospitalizations due to upper GI bleeding ... on selective serotonin reuptake inhibitors, or SSRIs, were 3.6-times ...
... by a Diabetes Research Centre in India has shown that ... had considerable improvement when they followed safe practices advised by ... doctors discovering that many patients came to the Centre with ... their lives. They decided that a little change in lifestyle ...
... called 'HERS' conducted by researchers of the University of California, ... that Hormone Replacement Therapy (HRT) may be able to reduce ... develop diabetes as well. ,The study involved some women ... had "impaired fasting glucose" - a condition with some ...
... 61 previous studies of blood pressure and cardiovascular disease, which ... regardless of age and even if readings are in the ... reducing risk of strokes and heart attacks. ,The study ... that out of the 120,000 who died, 56,000 suffered fatal ...
... Chairman and Managing Director of Eli Lilly and Co., India, ... cut in the company's human insulin product 'Huminsulin', that its ... market by the end of this year. He added that ... use of human insulin products and the phasing out of ...
Cached Medicine News:Health News:Women on HRT should avoid alcohol 2
(Date:7/21/2014)...  An International Trade Commission (ITC) ruling issued Friday ... device, Taiwanese device manufacturer APEX continues to infringe ResMed ... ) is the innovation leader and pioneer in designing ... "Our research and development teams are ... of comfort, performance and efficacy," said David Pendarvis ...
(Date:7/21/2014)... Apex Medical Corporation (Apex, TWSE: 4106), a leading player ... announces that the United States International Trade Commission (USITC) ... newly designed XT series continuous positive airway pressure (CPAP) ... the patent claims asserted by ResMed, one of Apex,s ... an upgraded iCH water tank to the market in ...
(Date:7/18/2014)... 2014 Hanger, Inc. (NYSE: HGR ) ... operations for the quarter ended June 30, 2014, on Tuesday, ... to discuss these results is scheduled to begin at 9:00 ... participate should call 1-877-662-6095. A replay will be available until ... ID # 44683027. About Hanger, Inc. – Built ...
Breaking Medicine Technology:ITC Rules Redesigned APEX Humidifier Still Infringes ResMed Patents 2Apex Medical's Respiratory Therapy Product Receives Affirmation from USITC 2
... an international generic pharmaceuticals company, today announced that ... Food & Drug Administration to market Zolpidem Tartrate ... the product has commenced.   Actavis ... Extended-Release Tablets 6.25 mg strength in October 2010 with ...
... 6, 2011 Pharmacyclics, Inc. (Nasdaq: PCYC ... the Phase IB/II study of the Btk inhibitor, PCI-32765, ... (CLL/SLL) at the 2011 American Society of Clinical Oncology ... development program update for the Btk Inhibitor, PCI-32765.  The ...
Cached Medicine Technology:Actavis Receives FDA Approval of Zolpidem Tartrate Extended-Release Tablets USP, 12.5 mg CIV in the U.S. 2Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 2Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 3Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 4Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 5Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 6Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 7Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 8Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 9
... a multipurpose agarose, has been developed for ... and separation of high molecular weight DNA ... a high gel strength agarose ( 1800 ... the use of low concentrations of agarose ...
Inquire...
... Agarose is a premium agarose used for ... This agarose produces clear sharp bands, with ... lot of UltraClean Forensic Agarose is tested ... activity, RNase activity and DNA contamination. ...
... specifically formulated for high resolution of small ... This standard melting temperature agarose can resolve ... bp difference in size. UltraPure™ Agarose ... for better handling and improved clarity for ...
Medicine Products: